Effect of Miralax NPO Time on Residual Gastric Volumes and Bowel Preparation

NCT07616908 | Not Yet Recruiting

• 1 other identifier: 86683
• Study Type: interventional
• Target: 200
• Locations: 0 countries
• Sites: N/A

Brief Summary

The goal of this clinical trial is to assess differences in residual gastric volumes after stopping Miralax ingestion at different time points (2, 4, 6 hours) prior to anesthesia induction and compare it to the control (current institutional standard of care where no Miralax is given on the day of surgery).

Conditions

Residual Gastric Contents; Polyethylene Glycol

Keywords

residual gastric volume; miralax; polythylene glycol; gastric POCUS; pediatric; EGD; colonoscopy

Outcome Measures

Primary Outcomes (1)

• Residual gastric volume as measured by EGD

  To be performed at the start of the EGD immediately after anesthesia induction.

Secondary Outcomes (3)

• Preoperative gastric POCUS volume assessment

  Performed prior to anesthesia induction

• Effectiveness of colonoscopy cleanout

  Performed during the colonoscopy portion following upper GI endoscopy (EGD)

• Incidence of aspiration on induction and perioperative aspiration

  On anesthesia induction

Study Arms (4)

4hr NPO

ACTIVE COMPARATOR

Miralax will be stopped 4 hours prior anesthesia induction

Behavioral: Stopping Miralax ingestion 4 hours prior to anesthesia induction

6hr NPO

ACTIVE COMPARATOR

Miralax will be stopped 6 hours prior anesthesia induction

Behavioral: Stopping Miralax ingestion 6 hours prior to anesthesia induction

2hr NPO

ACTIVE COMPARATOR

Miralax will be stopped 2 hours prior anesthesia induction

Behavioral: Stopping Miralax ingestion 2 hours prior to anesthesia induction

Control

ACTIVE COMPARATOR

Miralax will not be given day of surgery

Behavioral: Control

Interventions

Stopping Miralax ingestion 2 hours prior to anesthesia induction BEHAVIORAL

Stopping Miralax ingestion 2 hours prior to anesthesia induction

2hr NPO

Stopping Miralax ingestion 4 hours prior to anesthesia induction BEHAVIORAL

Stopping Miralax ingestion 4 hours prior to anesthesia induction

4hr NPO

Stopping Miralax ingestion 6 hours prior to anesthesia induction BEHAVIORAL

Stopping Miralax ingestion 6 hours prior to anesthesia induction

6hr NPO

Control BEHAVIORAL

Miralax will not be given on the day of surgery

Control

Eligibility Criteria

• Age: Up to 18 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)

You may qualify if:

• Patients undergoing both EGD and colonoscopy
• Use of Miralax for cleanout
• Patients \<19 years old

You may not qualify if:

• Patients with a history of delayed gastric emptying (eg diabetic, GLP-1 intake)
• Patients with a history of gastric sleeve surgery
• Use of Golytely for cleanout
• Emergent EGD/colonoscopies
• EGD/colonoscopies for foreign body removal and/or decompression
• Known neurologic compromise
• Presence of pre-existing ostomy, short bowel syndrome, gastric retention, intestinal obstruction, ileus, bowel perforation, toxic colitis, toxic megacolon, swallowing difficulties
• Pre-existing electrolyte derangements
• Allergy to Miralax

Sponsors & Collaborators

• Stanford University: lead

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: CARE PROVIDER, OUTCOMES ASSESSOR
• Masking Details: The endoscopist, the anesthesiologist performing the gastric POCUS evaluation, the anesthesiologist, the research coordinator
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Clinical Associate Professor

Study Record Dates

• First Submitted: May 17, 2026
• First Posted: June 1, 2026
• Study Start: July 1, 2026
• Primary Completion (Estimated): June 1, 2028
• Study Completion (Estimated): June 1, 2028
• Last Updated: July 6, 2026

Record last verified: 2026-07